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Abstract. Stress-induced hyperglycaemia is commonly occurred in the intensive care unit 
(ICU). It is known that the intensive insulin therapy (IIT) has successfully managed the blood 
glucose level within the targeted band. However, modifications on the current practice need 
to be considered to minimize the risk of hypoglycaemia and mortality. Thus, the aim of this 
study is to assess the performance of a new practice known as Stochastic Targeted (STAR) 
Protocol in managing blood glucose levels in Malaysia ICU setting. STAR is a tablet-
computer based protocols that provides patient-specific glucose control framework 
accounting for patient variability with a stochastically derived maximum 5% risk of 
hypoglycaemia events. A retrospective 92 non-diabetes patient’s data who underwent IIT 
were identified. Patient’s blood glucose levels, exogenous insulin and nutrition inputs 
including patient demographics were extracted from the ICU charts to create virtual patients 
by using physiologically mathematical model. Three trials were simulated with controlled 
goal feed (GF) and without GF. Only one type of nutrition is considered in this study which 
is Glucerna. The outcomes will be compared in terms of %BG within the targeted band of 
4.4 to 10.0 mmol/L, the total number of BG measurements, and the % of severe 
hypoglycaemia. The results indicate that STAR virtual trial with controlled GF reduced the 
risk of hypoglycaemia to 3% and the clinical burden up to 1630 hours while maintaining BG 
within the targeted band. The total number of BG measurements also decreased to 5384 from 
7038. Thus, the implementation of STAR protocol in the Malaysia ICU is beneficial and it is 
proven safe while aiding nurses and physicians in reducing the clinical burden and medical 
cost in treating stress-induce hyperglycaemia in the demanding ICU setting. 
1. Introduction 
Patients with acute, life-threatening illnesses that admitted to the intensive care unit (ICU) required close 
monitoring from the medical staff. Around 20% of mortality cases in the ICU have been reported 
worldwide. Most of the causes of deaths were from circulatory system disorder, renal failure and critical 
illness attributable to the failure of multiple organ systems [1-3]. Despite special treatment given to the 
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patient, their poor body is in a stress state that leads to the stress-induced hyperglycaemia incidence [4, 
5]. 
 Hyperglycaemia event is a condition where human blood glucose level is high, while in the opposite 
condition, where human blood glucose level lower than the normal level is called hypoglycaemia. In the 
intensive care unit, stress-induce hyperglycaemia occurs when the patient in a stress response where 
patient's hepatic glucose production increased and inhibition of insulin secretion caused by the strong 
counter-regulatory hormones and lead to elevation of insulin resistance and blood glucose (BG) 
concentrations [1, 5]. This condition has been independently related to the rate of mortality in the ICU. 
The undesired episode can be reduced with the control of patient's BG, despite the process is difficult 
due to complex, and variable dynamic stress response experienced by the patients [6].  
 Over the years, there are new researches and methods were introduced to the medical community, in 
order to control a patient’s blood glucose. Currently, the most commonly used protocol is Intensive 
Insulin Therapy (IIT) that applied sliding scale method in determining the amount of insulin 
administrated to the patients based on the current measured blood glucose via finger prick. This 
conventional protocol, which is a manually automated system, that requires closed supervision and 
monitoring by the medical staffs. Furthermore, this protocol is considered as a standard protocol to 
control ICU patient’s BG levels in Malaysia ICU. 
 Although IIT has been successfully maintained patient's BG level within a safety range [4], but IIT 
also has high possibility to lead an undesired incident such as severe hypoglycaemia event [7-9] that 
will lead to the increased mortality cases. The implementation of sliding scale method in managing 
blood glucose in the ICU is commonly in hourly-basis. In fact, this method is incapable in predicting 
the next hour blood glucose level given a certain amount of exogenous insulin based on the level of 
severity of BG measurement [10, 11]. Thus, this therapy indirectly create clinical burden in terms of 
monitoring and managing BG levels in the ICU setting, especially for patients with comorbidities that 
requires special attention from the nurses and physicians. Thus, to encounter this clinical burden and at 
the same time provide a safe treatment, a clinical validated protocol which has been used widely in New 
Zealand, Hungary, Belgium and other countries [6, 12-14] known as STAR protocol.  
 Stochastic TARgeted (STAR) protocol is a flexible model-based tight glycaemic control framework 
accounting for patient variability with a stochastically derived maximum 5% risk of BG below minimum 
safety requirement. This tablet-computer-based protocol provides patient-specific glucose control. It 
uses a clinically validated pharmacokinetic and pharmacodynamic model of the insulin-glucose system 
and a cohort-based model of insulin sensitivity variability to compute optimal patient-specific insulin 
and nutrition [14]. Since 2011, Christchurch Hospital ICU, Christchurch, New Zealand and Kalman 
Pandy Hospital, Gyula, Hungary currently have been using STAR protocol as their standard care in the 
ICU [6]. 
 Thus, this study is mainly focused on assessing STAR performance in Malaysian ICU's cohort 
(specifically in Hospital Tengku Ampuan Afzan, Kuantan, Pahang, Malaysia) by using in-silico 
preclinical trials. Specifically, the nutrition intake will be modified by selecting only one type of 
nutrition i.e. Glucerna and the rate will be corrected via controlled goal feed calculation. The outcome 
of this study is expected to reduce the undesired effects which will improve the patient condition and to 
improve the current manual-automated BG control protocol to an automated system where it can reduce 
clinical workload and medical costs significantly [15]. The STAR protocol has been proven in delivering 
positive outcomes especial in reducing the mortality rate in the ICU [6, 12-14, 16-18]. Moreover, it is 
considerably having a high potential in Malaysia ICU setting because of the ability of STAR framework 
that has been proven safe with significant reductions in hypoglycaemia and mortality cases due to its 
characteristics, which can forward predict changes in patient's metabolic changes [16, 19, 20]. 
 
2. Methodology 
2.1 Physiological Model 
The real-time Intensive Care Insulin-Nutrition-Glucose (ICING) model is used to simulate a critically 
ill patient’s BG level to identify their hourly insulin sensitivity, SI [5, 21-23]. SI is a condition where 
glucose content in the human blood triggers the pancreas to secrete insulin which stimulates cells to 
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absorb blood glucose. The model equations are defined in Equation (1) – (7) and its graphical overview 
is presented in Figure 1. 
 
                 
?̇? = −𝒑𝒈𝑮(𝒕) − 𝑺𝑰𝑮(𝒕)
𝑸(𝒕)
𝟏 + 𝜶𝑮𝑸(𝒕)
𝑷(𝒕) + 𝑬𝑮𝑷 − 𝑪𝑵𝑺
𝑽𝑮
 
 
(1) 
?̇? = 𝒏𝑰(𝑰(𝒕) − 𝑸(𝒕)) − 𝒏𝑪
𝑸(𝒕)
𝟏 + 𝜶𝑮𝑸(𝒕)
 
 
(2) 
?̇? = −𝒏𝑲𝑰(𝒕) − 𝒏𝑳
𝑰(𝒕)
𝟏+𝜶𝑰𝑰(𝒕)
− 𝒏𝑰(𝑰(𝒕) − 𝑸(𝒕)) +
𝒖𝒆𝒙
𝑽𝑰
+ (𝟏 − 𝒙𝑳)
𝒖𝒆𝒏(𝑮)
𝑽𝑰
) 
 
 
(3) 
 
𝑷𝑰(𝒕)  = −𝒅𝟏𝑷𝟏 + 𝑫(𝒕) 
 
 
(4) 
𝑷𝟐(𝒕) = −𝒎𝒊𝒏(𝒅𝟐𝑷𝟐, 𝑷𝒎𝒂𝒙) + 𝒅𝟏𝑷𝟏 
 
 
(5) 
𝑷(𝒕) = 𝒎𝒊𝒏(𝒅𝟐𝑷𝟐, 𝑷𝒎𝒂𝒙) + 𝑷𝑵(𝒕) 
 
 
(6) 
𝒖𝒆𝒏(𝑮) = 𝒎𝒊𝒏 (𝒎𝒂𝒙(𝟏𝟔. 𝟔𝟕, 𝒌𝟏𝑮(𝒕) − 𝒌𝟐), 𝟐𝟔𝟔. 𝟔𝟕) 
 
(7) 
where the model nomenclatures can be referred as in [10]. 
 
 
Figure 1. ICING model physiological schematic diagram [15]. 
 
 Basically, the physiological model as listed in equations (1) – (7) (i.e. in Figure 1) used in this study 
has three main compartments which represents the blood glucose mechanism with the ability to capture 
the long-term dynamics and progress of a critically ill patient's glucose-insulin response. The main 
compartments are identified as blood glucose (G), plasma insulin (I) and plasma intersitital insulin (Q). 
The inputs for G in which rise the blood glucose level is through enteral nutrition given to the patients 
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and the endogenous glucose production (EGP) by the liver. In return, the glucose is used by central 
nervous system (CNS), and other insulin-dependent glucose cells. In fact, the glucose also being cleared 
via receptor-bound insulin through liver and kidney. Once, the blood glucose level is rise plasma insulin 
will be trigger and release to maintain the blood glucose in maintaining glucose homeostasis. Plasma 
insulin is produced from pancreas. If insulin is not enough exogenous insulin (Actrapid) will be 
introduced to the patient. Plasma insulin is cleared by liver and kidney after glucose homeostasis 
achieved. This mechanism is continuously repeated once patient consumed food or nutrition.  
 Moreover, this validated physiological model as listed in equation (1) – (7) known as ICING has 
achieved low fitting and low prediction error based on prior studies [8, 10–12, 15-17] when clinical data 
(blood glucose levels, nutrition and exogenous insulin inputs) obtained from the patients is fitted to 
ICING model. 
 
2.2 Virtual patients 
Virtual patients are simulated by using Hospital Tengku Ampuan Afzan (HTAA)’s retrospective clinical 
data of 92 non-diabetes patients as shown in Table 1 who underwent IIT to carry out STAR in-silico 
virtual trials. An hourly treatment-independent SI profile is identified through the virtual patients created 
from the clinical data, allowing virtual trials to realistically simulate patient response based on the given 
treatment. 
 After taking into consideration of some physiological factor, comorbidity of patients is filtered based 
on their previous history and patient with a history of diabetes mellitus is neglected while patient's length 
of stay is limited to five days. 
 There are two types of nutrition that are commonly given to the ICU patients: enteral and parenteral 
nutrition. Patients who were given parenteral nutrition are neglected in this study. The current clinical 
practice in HTAA used specifically five types of enteral nutrition (refer to Table 2), which are Glucerna, 
Jevity, Diabetic Resource, Nepro, and Ensure but for the virtual patient’s simulation, the study only 
considered Glucerna. In addition, the daily nutrition intake for a critically ill patient is based on the 
specific goal feed, GF (kcal) recommended by ESPEN [24] that can be determine based on the body 
weight. If indirect calorimetry is not available, the use of the 25kCal/kg/day for daily calorie intake for 
a patient is adequate. For example a 60kg patient needs 1500kCal/day to be consumed in a day (i.e. 60kg 
х 25kCal/kg/day = 1500kCal/day). The glucose content in Glucerna is 0.0872 g/mL for each 1 kCal/mL. 
Thus, a 60 Kg patient require approximately 5.08g (or 121.9g) of glucose in an hour which can be 
calculated as shown in equation (8). 
 
1500𝑘𝐶𝑎𝑙 𝑑𝑎𝑦⁄
24 ℎ𝑟 𝑑𝑎𝑦⁄
÷ (1 𝑘𝐶𝑎𝑙 𝑚𝐿⁄ ) = 62.5 𝑚𝐿 ℎ𝑟 ×  (0.0812 𝑔 𝑚𝐿⁄ ) = 5.08 𝑔 ℎ𝑟 𝑜𝑓 𝑔𝑙𝑢𝑐𝑜𝑠𝑒⁄⁄          (8)
Table 1. Patient demographics. 
 HTAA cohort 
Total patients 92 
Weight (mean) 
Age (years - mean) 
67.7kg 
 50 years old 
% Male 59.8% 
With Comorbidity 45.7% 
Mortality 
Length of Stay (mean) 
41.3% 
4.6 days 
   
 Num. patients % 
   Medical 53 58% 
   Surgical 28 30% 
   Gastrointestinal 1 1% 
   Neurological 10 11% 
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Table 2. Nutrition information used in HTAA. 
Nutrition kCal/mL  Glucose content (g/mL) 
Glucerna 1 0.0812 
Jevity 1.5 0.216 
Diabetic Resource 1 0.0872 
Nepro 1.8 0.0863 
Ensure 1 0.097 
  *Full product information can be obtained from the Abbott & Nestle websites respectively. 
 
2.3 Stochastic model 
STAR protocol using stochastic forecasting which provides a control framework for future outcomes 
mainly to mitigate hypoglycaemia cases. This protocol minimise risk of hypoglycaemia cases (5% for 
BG < 4.44 mmol/L, ≈ 1% for BG < 4.0 mmol/L). 
 Current SI parameter from ICING model will be identified once a BG measurement is entered, and 
a range of SI values (used for future prediction) is generated using a stochastic model. The range of 
predicted SI is then used together with the ICING model to generate BG results and most suitable 
therapy correlate with potential insulin and nutrition administration combinations. The result outcomes 
balance clinical assignment, nutrition rates, and BG variability. Using the range of SI generated 
previously, simulation of a range of BG outcomes begins. For every tolerable insulin rate, the BG 
outcomes are simulated between the 5th percentile (refer to Figure 2, points A-C) and 95th percentile 
(refer to Figure 2, points D-F) [18, 19]. 
 If BG outcome is below the targeted range (5th - 95th percentile), the combination of insulin and 
nutrition administration is discarded and the simulation of algorithm moves on. Otherwise, if the 
outcomes are within the tolerance range, the combination is saved [18]. Eventually, if the prediction 
closer to the lower limit than any previous combinations, it is saved as a possible treatment. 
 The skewed nature of the BG results distribution makes the 5th percentile target is prioritized for 
control. As shown in Figure 2, it ensures BG level to be in the desired target range of the 4.44 - 8 mmol/L 
that specifically reduced the acuteness of organ failure. 95th percentile target ensures the tightness of 
glycaemic control which limits the possibility of mild hyperglycaemia event. [18, 19].  
 
 
Figure 2. The generated BG forecast (points A to F) within the target 5th-95th percentiles: 80-145 
mg/dL (i.e. 4.44-8.0 mmol/L) [19].  
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2.4 Virtual trials 
Before clinical testing (Figure 3) is commenced, in-silico virtual trials should be conducted to prove the 
study performance and to ensure the patient’s safety. The virtual trial simulations will be compared to 
the raw clinical data obtained from the ICU chart to validate the outcomes to observe the improvement 
on the improvised blood glucose management by using STAR with controlled goal feed. In addition, the 
performance of STAR with controlled goal feed and without GF will be compared and analysed.  
 
 
Figure 3. Virtual trial simulations procedure. 
 
2.5 Performance metrics 
Performance of STAR virtual trial simulations is classified within the percentage of BG level that must 
be in the targeted range. Clinical labour performance will be assessed by the frequency of BG 
measurements and the patient’s safety will be assessed based on the level of hypoglycaemia event; 
severe = (BG < 2.2mmol/L), mild = (BG < 4.0mmol/L). 
3. Results and discussion 
 
3.1 Performance of STAR protocol 
Based on the insulin-glucose rates tabulated in Table 2, it shows that STAR with controlled GF (5.7 – 
8.7 mmol/L) offers tight and safe glycaemic control that helps to reduce hypoglycaemia and 
hyperglycaemia incidences in the ICU. It is also proven by prior study by [12, 13, 16, 18, 20]. For 
instance, the amount of exogenous insulin administrated of STAR with controlled GF is less compared 
to the other two virtual trial simulations, which leads to low (four cases in STAR-GF and eight cases for 
the other two) severe hypoglycaemia incidences. In fact, the glucose rate in STAR with controlled GF 
has the highest amount of glucose of 5.8 g/hour, which approximately close to the calculated nutritional 
goal feed of 5.08 g/hr as explained earlier in section 2.2. 
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Table 3. The overall performance of STAR without and with controlled GF. 
  STAR STAR STAR 
Whole cohort statistics Original Glucerna Glucerna_GF 
# patients: 92 92 92 
Total hours: 11594 11594 9964 
# BG measurements: 7038 6875 5384 
BG median 7.4 7.3 7.1 
[IQR] (mmol/L): [6.0 - 9.2] [5.9 - 9.1] [5.7 - 8.7] 
Desired glycemic bands:       
% BG in 6.0-10.0mmol/L 57.6 57.2 56.8 
% BG in 4.0-5.9mmol/L 21.9 23.5 26.3 
Hyperglycemic bands:       
% BG > 10.0mmol/L 17.7 16.5 13.6 
Safety glycemic bands:       
% BG < 4.0mmol/L 2.8 2.8 3.3 
# patients < 2.2mmol/L 8 8 3 
Interventions:       
Median insulin rate  5 4.5 4 
[IQR] (U/hr): [2.0 - 8.0] [2.0 - 8.0] [2.0 - 7.5] 
Median glucose rate  3.9 4.5 5.8 
[IQR] (g/hour): [1.9 - 6.6] [1.9 - 6.6] [3.9 - 6.6] 
Median glucose rate  60% 70% 89% 
[IQR] (% goal): [30-100] [30-100] [60-100] 
 
3.2 Safety  
Simulation of STAR based on HTAA clinical data ensures the patient’s safety in reducing hypoglycemia 
cases especially patient with controlled GF. Prior study [6, 14] proven that ≈ 1% of hypoglycemia case 
reported when STAR is introduced. However, there are three patients (≈ 3%) will be experiencing 
hypoglycaemia. Although the chance of getting hypoglycaemia is slightly higher in Malaysia ICU this 
is due to the level of comorbidities experienced by Malaysian patients by referring to Table 1 about 
45.7% patients associated with comorbidities, which are far more severe, compared to the other 
countries that used STAR [6, 18].  
 In terms of mortality, the IIT protocol implementation at the HTAA ICU has reported high mortality 
rate of 38 cases (41.3%). However, the prior studies on the STAR implementation in several hospitals 
in Christchurch, NZ and Gyula, Hungary indicated low mortality rate of 6.4% (Christchurch) and 0% 
(Gyula) [6, 19]. Thus, this outcome proves that STAR is effectively safe to be implemented in Malaysia 
ICU as it can reduce the mortality rates significantly. 
 
3.3 Clinical effort 
Table 2 shows a decreasing number of total hours and blood glucose measurement which is the actual 
time for the nurses have to spend at the patients' bedside. The significant changes occur in terms of total 
BG measurements taken is reducing from 7038 to 5384. In fact, the total hour’s patient will undergo 
therapy in reducing and maintaining their blood glucose levels within targeted band is reduced 
significant by 1630 hours. Based on prior study, STAR reduces the measurements per day by 7%, which 
decrease nurse’s workload and clinical burden [14, 15, 25].  
 Previously with IIT protocol, HTAA patients are given more than five types of nutrition based on 
their comorbidities. Each type of nutrition as listed in 2.2 has a different amount of glucose content. The 
reason of using different types of nutrition is to tolerate with the patient’s comorbidities in order to 
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minimize the risk of getting worse, for example, a patient with acute kidney injury (AKI) required only 
1.4 – 1.8g/kg/day [26] of protein intake. Thus, each type of nutrition is formulated based on the targeted 
group. However, only Glucerna is considered in this study as to standardize the STAR protocol with the 
minimum glucose requirement for all patients. This is done by neglecting the types of nutrition that 
patients supposed to take based on their comorbidities. Surprisingly, the performance of STAR with 
controlled GF that used only Glucerna as nutrition input is significantly improved compare to the other 
two trials underwent STAR in terms of reducing hypoglycaemia and the total of BG measurements take 
as explained earlier.   
 In addition, the introduction of controlled GF which is taken into account the amount of nutrition 
(i.e. the glucose content) required by the patient and the patient’s body weight (refer to 2.2) This goal 
feed is necessary to be determined before STAR is commenced to ensure that patient will feed well and 
fully recovered during their stay in the ICU. In addition, the aim of controlled goal feed is to avoid the 
significant weight loss due to deficient amount of nutrition given to the patient. However, excessive 
glucose in the blood will lead to hyperglycemia incident meanwhile insufficient amount of nutrition will 
cause hypoglycaemia. Thus, it is the best practice for the physicians to determine the patient-specific 
GF before starting any treatment to the patients to avoid any mishaps that would give harm to the patient. 
 
4. Conclusions 
The performance of STAR shows significant reduction of 23% on the total BG measurements taken 
which consequently reduced the clinical burden. The protocol also has reduced the hypoglycaemia 
events to only 3 patients once STAR is introduced with controlled goal feed based on patient-specific. 
Thus, by implementing STAR protocol in the Malaysia ICU will help nurses and physicians in 
controlling BG levels in the chaotic ICU setting as STAR protocol is proven safe to all critically ill 
patients with or without comorbidities. However, the study is limited to only one general hospital in 
assuming that the other Malaysia general hospital follows the standard IIT protocol. In fact, the patient 
races: Malay, Chinese and Indian, and other demographics factors that might arise in the other general 
hospital are not considered in the study that might affect the outcomes of the study. Thus, a larger cohort 
from other general hospitals from different states, which considered every demographic and comorbidity 
aspects should be considered in the future study to validate the results obtained in this study.    
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